compounded semaglutide crackdown news today The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new (Wegovy) weight-loss pill from the FDA crackdown on off-brand Ozempic

Araj-Khodaei, M., Ayati, M

Red Flags When Evaluating a Peptide Vendor The FDA's 2025 and 2026 enforcement actions targeted suppliers whose labeling or website language implied human use, suggested therapeutic effects, or marketed the compound by comparison to FDA-approved drugs

Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review

If a provider prescribes compounded semaglutide, it is prepared and shipped by a licensed US compounding pharmacy

GLP-1 medications may help improve lipid profiles in some patients, though effects vary significantly based on individual metabolic factors

Laura Franzese, in Portland, Ore., learned about the licensing problem after spending $1,000 on a bulk order of tirzepatide from Zappy that arrived with Ousia labels